[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"sar-cov-2\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:sar-cov-2":49},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":10,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":30,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":40,"startDateStruct":43,"completionDateStruct":44,"leadSponsor":46,"locationsCount":5},"100617152",false,"NCT07314905","Adaptive Platform Trial of Treatments for Respiratory Infections in Community Settings (TreatResp)","Adaptive Platform Trial of Treatments for Respiratory Infections in Community Settings","TreatResp","Inclusion Criteria:\n\n* 18 years or older\n* A positive test (PCR or RAT) for one of the pathogens included in the trial's domains (influenza A\u002FB, or other future specified respiratory pathogens),\n* Enrolled within 5 days of symptoms onset. However, this window may vary depending on the domain or specific interventions within each domain (for example 72 hours for Baloxavir).\n* At least two symptoms commonly associated with respiratory infections, including:\n\n  * rhinitis\n  * cough\n  * wheezing\n  * sore throat\n  * nasal congestion\n  * shortness of breath\n  * fatigue\n  * rapid breathing\n  * excessive mucus production\n  * loss of smell or taste\n  * hemoptysis\n  * trouble sleeping or insomnia due to breathing difficulties\n  * fever (defined for purposes of this study as \\>37.5°C\u002F 41).\n\nExclusion Criteria:\n\n* Admitted to hospital or in an ED for more than 24 hours\n* Previously randomized to TreatResp within the past 12 months\n* Currently participating in a clinical trial of a therapeutic agent for acute respiratory pathogen infection that is not\u002Fsuspected not compatible with the study therapeutics\n* Already taking a study therapeutic or contraindication to a study therapeutic\n* Inability for participant or caregiver to provide informed consent.\n\nAdditional eligibility criteria will be applied based on the intervention assigned. For instance, if a participant is randomized to an antiviral treatment, they must not have contraindications specific to that antiviral. This ensures that each treatment is evaluated in a population for whom it is most appropriate and safe.\n\nBaloxavir exclusion:\n\n* Has a known or suspected pregnancy\n* Is breastfeeding\n* Is of childbearing potential and is not willing to use a highly effective contraceptive\n* Has advanced chronic kidney disease (CKD stage 3: eGFR ≥30 to \\\u003C60 mL\u002Fmin, and severe renal impairment (eGFR \\\u003C30 ml\u002Fmin, CKD stage 4-5)\n* Has severe hepatic impairment, or requires a live viral vaccine within the next seven days\n* Has a significant impaired immunity (e.g., due to long-term oral steroids, chemotherapy, or an immune disorder)\n* Requires immediate antiviral treatment or hospitalization as per the clinician's judgment\n* Is allergic to trial medications\n* Is scheduled for elective surgery or procedures requiring general anesthesia within the next two weeks\n* Is co-infected with viruses of interest\n* Received a live viral vaccine within the last 14 days","ALL","18 Years",{"count":19,"type":20},264,"ESTIMATED","INTERVENTIONAL",[23],"PHASE3","TreatResp is a double-blind, individually randomized, multi-centre adaptive platform trial. TreatResp aims to establish an adaptive platform trial aimed at evaluating the clinical- and cost-effectiveness, practical challenges, and outcomes of therapeutics for respiratory pathogens in non-hospitalized patients. Participants will be randomized to receive usual care (i.e., supportive care and symptom relief) or a study therapeutic, which will be determined by the TreatResp Therapeutics Committee. The primary outcomes being evaluated is time to recovery.",[26,27,28,29],"Influenza A","Influenza B","SAR-CoV-2","Acute Respiratory Infections (ARIs)",[31,32,26,27,33,34,35,36,37],"COVID-19","SARS-CoV-2","Influenza","Respiratory pathogens","Respiratory infections","Adaptative Platform Trials (APT)","acute respiratory infections (ARIs)","NOT_YET_RECRUITING","2025-12-31",{"date":41,"type":42},"2026-01-02","ACTUAL",{"date":41,"type":20},{"date":45,"type":20},"2027-04-24",{"name":47,"class":48},"Unity Health Toronto","OTHER",""]